{"prompt": "['5.4 HCV Virologic Response-Based Treatment Stopping Criteria', 'Treatment will be stopped if there is a less than 1 log10 decline in HCV RNA after 4 weeks of therapy.', 'Confirmation should be performed as soon as possible and must occur no later than 2 weeks after an', 'initial observation indicating virologic failure. All subjects who terminate treatment early will complete', 'the Early Termination (ET) Visit, Week 4 and Week 12 Post-Treatment Visits.', '5.5 Treatment Discontinuation Criteria', 'The Medical Monitor should be consulted prior to subject discontinuation when medically feasible. Study', 'drug must be discontinued in the following instances:', 'Unacceptable toxicity, as defined in Section 9 of the protocol, or toxicity that, in the judgment of', 'the Sponsor-Investigator or Sub-Investigator(s), compromises the ability to continue study-', \"specific procedures or is considered to not be in the subject's best interest\", 'Pregnancy of female subject', 'HCV efficacy failure as defined in Section 5.3', 'Significant protocol violation', 'Subject request to discontinue for any reason; it is important to determine and document', 'whether the withdrawal of consent is primarily due to an adverse event (AE), lack of efficacy, or', 'other reason', 'Discontinuation of the study at the request of CRI, regulatory agency, or an Institutional Review', 'Board (IRB)/Independent Ethics Committee (IEC)', 'If a subject meets discontinuation criteria during treatment, an Early Termination Visit will be required', '(Section 8.2.4). Early Termination Visits should be scheduled as soon as possible following', 'discontinuation of treatment. Subjects that discontinue treatment early are still required to complete', 'Post-Treatment Weeks 4, and 12 Visits.', '6 SUBJECT POPULATION', '6.1 Number of Subjects and Subject Selection', 'Approximately 20 subjects with chronic HCV infection will be enrolled, including individuals who have', 'compensated cirrhosis and who have been previously treated with pegylated-interferor and ribavirin', 'an HCV protease inhibitor. Due to the limited resources available for this proof of concept pilot study,', 'only English-speaking participants will be considered for enrollment.', '6.2 Inclusion Criteria for clinical subjects', '1. Willing and able to provide written informed consent', '2. Age 18 years', '3. Confirmation of chronic HCV infection as documented by a positive HCV', 'antibody test at least 6 months prior to the Baseline/Day 1 visit OR by', 'patient report of infection for at least 6 months prior to the baseline/day 1', 'visit AND positive HCV RNA test at screening', '4. HCV genotype 1, 2, 3, 4, 5 or 6', '5. In stable remission from opioid use on buprenorphine/naloxone for at least', '12 weeks', 'CRI 15-05 Protocol 13SEP2017', 'Page 19']['6. Within the following laboratory parameters as assessed at the screening', 'visit:', 'a.', 'HCV RNA quantifiable', 'b. Screening rhythm strip without bradycardia (heart rate > 60 or, if on', 'beta blocker, > 55 BPM)', 'C.', 'ALT < 10 X ULN', 'd.', 'AST < 10 X ULN', 'e.', 'Direct bilirubin 1.5 X ULN', 'f.', 'Platelets > 60,000', 'g.', 'HbA1c < 13%', 'h.', 'Creatinine clearance 30 mL/min, as calculated by the Cockcroft-', 'Gault equation', 'i.', 'Albumin 3g/dL', 'j.', 'INR < 1.5 X ULN or on an anticoagulant regimen affecting INR', '7.', 'Female subject is eligible to enter if it is confirmed that she is:', 'a.', 'Not pregnant or nursing', 'b. Not of childbearing potential (i.e. s/p hysterectomy, oophorectomy', 'or has medically documented ovarian failure, or are postmenopausal', 'women > 50 years of age with cessation of menses for 12 months or', 'greater)', 'OR', 'Of childbearing potential with a negative serum pregnancy test', 'within 2 weeks of screening, a negative urine pregnancy test on Day', '1, and a commitment to either abstain from intercourse or', 'consistently use an acceptable method of birth control (Appendix 4)', 'in addition to condom use by her male partner(s) from the date of', 'screening until 30 days after the last dose of study drug', '8.', 'All male study participants must agree to consistently and correctly use', 'condoms with their female partner(s) of childbearing potential and such', 'female partner(s) must agree to use an acceptable method of birth control', '(listed) from the date of screening until 90 days after the last dose of study', 'drug', '9.', 'Male subjects must refrain from sperm donation from the date of screening', 'until 90 days after the last dose of study drug', '10. Subject must be in generally good health, with the exception of HCV, in the', 'opinion of the Sponsor-Investigator or Sub-Investigator(s)', '11. Subject must be able to comply with dosing instructions for study drug', 'administration and able to complete the study visits, including all required', 'post-treatment visits', 'Subjects must meet all of the above inclusion criteria to be eligible for participation in this study.', '6.3', 'Exclusion Criteria for clinical subjects', '1. Presence of decompensated cirrhosis as defined by encephalopathy, ascites,', 'or a history of a variceal bleed', 'CRI 15-05 Protocol 13SEP2017', 'Page 20']\n\n###\n\n", "completion": "END"}